myelodysplastic syndromes (MDS) | Page 102 | Aplastic Anemia and MDS International Foundation

myelodysplastic syndromes (MDS)

Microarray-based comparative genomic hybridization of cancer targets reveals novel, recurrent genetic aberrations in the myelodysplastic syndromes

Author(s): 
Kolquist KA, Schultz RA, Furrow A, Brown TC, Han JY, Campbell LJ, Wall M, Slovak ML, Shaffer LG, Ballif BC
Primary Author: 
Kolquist KA
Journal Title: 
Cancer Genet
Original Publication Date: 
Nov 2011

The

Bone Marrow Diseases: 

Classification of childhood aplastic anemia and myelodysplastic syndrome

Author(s): 
Niemeyer CM, Baumann I
Primary Author: 
Niemeyer CM
Journal Title: 
Hematology Am Soc Hematol Educ Program
Original Publication Date: 
Dec 2011

Hypoplastic BM disorders in children and adolescents comprise a broad spectrum of disorders. Acquired severe

Update on developments in the diagnosis and prognostic evaluation of patients with myelodysplastic syndromes (MDS): Consensus statements and report from an expert workshop

Author(s): 
Platzbecker U, Santini V, Mufti GJ, Haferlach C, Maciejewski JP, Park S, Solé F, van de Loosdrecht AA, Haase D
Primary Author: 
Platzbecker U
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2011

Several new treatments for

Bone Marrow Diseases: 

The long term risk of myelodysplastic syndromes among anemia patients: A population-based study.

Author(s): 
Meytes D, Chodick G, Shalev V, Porath A
Primary Author: 
Meytes D
Journal Title: 
Leuk Res
Original Publication Date: 
Dec 2011

We have utilized the computerized data of a nationwide health plan to elucidate several epidemiologic aspects and risk factor of

Bone Marrow Diseases: 

Histone methylation in myelodysplastic syndromes

Author(s): 
Wei Y, Gañán-Gómez I, Salazar-Dimicoli S, McCay SL, Garcia-Manero G.
Primary Author: 
Wei Y
Journal Title: 
Epigenomics
Original Publication Date: 
Apr 2011

Histone methylation is a type of epigenetic modification that is critical for the regulation of gene expression. Numerous studies have demonstrated that abnormalities of this newly characterized epigenetic modification are involved in the development of multiple diseases, including cancer. There is also emerging evidence for a link between histone methylation and the pathogenesis of myeloid neoplasms, including

Bone Marrow Diseases: 

Erythropoiesis-stimulating agents are not associated with increased risk of thrombosis in patients with myelodysplastic syndromes

Author(s): 
Weiss Smith S, Sato M, Gore SD, Baer MR, Ke X, McNally D, Davidoff A
Primary Author: 
Weiss Smith S
Journal Title: 
Haematologica
Original Publication Date: 
Nov 2011

Background. There are limited reports of thrombosis among myelodysplastic syndrome patients exposed to erythropoiesis stimulating agents.

Bone Marrow Diseases: 

Optimizing management of myelodysplastic syndromes post-allogeneic transplantation

Author(s): 
Sockel K, Ehninger G, Hofbauer LC, Platzbecker U
Primary Author: 
Sockel K
Journal Title: 
Expert Rev Hematol
Original Publication Date: 
Dec 2011

Allogeneic hematopoietic stem cell transplantation is still the only potentially curative treatment for patients with

Bone Marrow Diseases: